Released : April 30, 2018 07:00 RNS Number : 4680M MaxCyte, Inc. 30 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of AGM and 2017 Annual Report and Accounts Gaithersburg, Maryland - 30 April 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life
Released : April 25, 2018 07:00 RNS Number : 9826L MaxCyte, Inc. 25 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Appoints Dr Claudio Dansky Ullmann as Chief Medical Officer · Dr Dansky Ullmann joins the Company as MaxCyte prepares for clinical testing of its first
Released : April 04, 2018 07:00 RNS Number : 7161J MaxCyte, Inc. 04 April 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2017 Gaithersburg, Maryland - 04 April 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines
Released : March 15, 2018 07:00 RNS Number : 7489H MaxCyte, Inc. 15 March 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Full Year Results Gaithersburg, Maryland - 15 March 2018: MaxCyte (LSE: MXCT, MXCR), a global cell-based medicines and life sciences company , will be
Released : February 28, 2018 17:00 RNS Number : 3007G MaxCyte, Inc. 28 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Maryland, USA , 28 February 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that J.
Released : February 15, 2018 07:00 RNS Number : 9370E MaxCyte, Inc. 15 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA , 15 February 2018 - MaxCyte (LSE: MXCT, MXCR) the global cell-based medicines and technology company, announces that it
Released : February 13, 2018 07:00 RNS Number : 6464E MaxCyte, Inc. 13 February 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Dr Richard Douglas Joins MaxCyte Board Dr Douglas previously served as Senior Vice President of Corporate Development at Genzyme Gaithersburg, Maryland - 13
Released : February 01, 2018 16:06 RNS Number : 6932D MaxCyte, Inc. 01 February 2018 SCHEDULE 6 AIM BLOCK ADMISSION SIX MONTHLY RETURN Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b. Name of scheme(s) MaxCyte Long Term Incentive Plan c.
Released : January 23, 2018 13:32 RNS Number : 6888C MaxCyte, Inc. 23 January 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Maryland, USA - 23 January 2018: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 18,293 new shares of common
Released : January 22, 2018 07:00 RNS Number : 4641C MaxCyte, Inc. 22 January 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Gaithersburg, Maryland - 22 January 2018: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery,
